 | |||||||||
Vancouver, Canada – TheNewswire - February 4, 2025 – DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the “Company”), a leader in developing cutting-edge point-of-care eye diagnostic solutions, is pleased to announce the completion of the plastic injection mold for the production of its first 100,000 TeaRxTM Red Eye diagnostic devices. This achievement marks a milestone in the Company’s operational and commercial readiness, setting the stage for large-scale manufacturing of the innovative TeaRxTM Red Eye product.
TeaRxTM Red Eye is a novel, multi-parameter diagnostic test designed for the differential diagnosis of Adenoviral Conjunctivitis, Herpetic Keratitis, and Allergic Conjunctivitis. Primarily intended for use in primary care settings, the device is also tailored to meet the needs of ophthalmologists, offering a quick, simple, and effective tool for diagnosis of red eye.
DiagnosTear's TeaRxTM Red Eye diagnostic device utilizes advanced technology that allows for the analysis of extremely small volumes of tear fluid; often just a few microliters, making it ideal for point-of-care use. The device efficiently extracts minute amounts of biological material from a swab into a minimal volume of assay buffer, maximizing the concentration of biomarkers for sensitive detection. This makes it particularly well-suited for detecting infectious agents in tears, though it can also be used with other biological fluids.
"We are proud to achieve this important milestone in the development of the TeaRxTM Red Eye diagnostic product," said Dr. Shimon Gross, CEO of DiagnosTear. "Our team has worked diligently to bring this product to life, and with the successful finalization of the manufacturing of the critical tooling required for mass production of the test device, we are poised to take the next steps toward revolutionizing the way red eye is diagnosed and treated."
The TeaRxTM Red Eye diagnostic device is protected by a patent, further underscoring the Company's commitment to innovation in the field of ocular health. Looking ahead, DiagnosTear is preparing to initiate clinical trials in 2025 to pursue FDA clearance and CLIA waiver for the device, marking the next phase of its journey toward widespread availability.
About DiagnosTear Technologies
DiagnosTear Technologies is a global leader in the development and commercialization of rapid, point-of-care, multi-parametric diagnostic tests for ocular diseases. By leveraging the analysis of tear fluid composition, DiagnosTear provides innovative solutions for diagnosing conditions like Dry Eye and Red Eye. The company is committed to improving patient outcomes and transforming ophthalmic care through advanced, accessible diagnostic technologies.
For more information, please contact:
Dr. Shimon Gross
Chief Executive Officer
DiagnosTear Technologies Inc.
Email: shimon@diagnostear.com
DiagnosTear Investor Relations
Email: ir@diagnostear.com
###
Copyright (c) 2025 TheNewswire - All rights reserved.
